Table 2 Characteristics of patients... | American Society of Hematology

Table 2

Characteristics of patients studied for single-KIR 2DL1⁺ NK cells

UPN no.	13	25	37	3	17	18	23	55
Predicted NK alloreactivity	yes	yes	yes	no	no	no	no	no
KIR 2DL1 ligand status, don/pat	+/−	+/−	+/−	+/+	+/+	+/+	+/+	+/+
Diagnosis	AML	AML	AML	AML	AML	ALL	AML	MDS
Status at transplantation	Rel	CR2	CR2	Ref/per	CR1	CR2	CR1	CR1
Graft composition
CD34⁺ cell dose, ×10⁶/kg	15.5	12.4	12.6	9.2	10.9	19.5	12.7	10.3
CD3⁺ cell dose, ×10⁴/kg	0.9	1.0	1.0	0.3	1.2	0.8	1.2	1.1
Day of KIR2DL1-single–positive NK cell analysis	94	75	91	95	97	93	150	90
No. of T-cell add-backs received at analysis	2	1	2	0	1	2	1	1
Day of T-cell add-backs	44, 72	25	56, 84	−	47	43, 72	45	34
Total T-cell add-back dose received at analysis	7	10	10	−	1	11	10	1

UPN no.	13	25	37	3	17	18	23	55
Predicted NK alloreactivity	yes	yes	yes	no	no	no	no	no
KIR 2DL1 ligand status, don/pat	+/−	+/−	+/−	+/+	+/+	+/+	+/+	+/+
Diagnosis	AML	AML	AML	AML	AML	ALL	AML	MDS
Status at transplantation	Rel	CR2	CR2	Ref/per	CR1	CR2	CR1	CR1
Graft composition
CD34⁺ cell dose, ×10⁶/kg	15.5	12.4	12.6	9.2	10.9	19.5	12.7	10.3
CD3⁺ cell dose, ×10⁴/kg	0.9	1.0	1.0	0.3	1.2	0.8	1.2	1.1
Day of KIR2DL1-single–positive NK cell analysis	94	75	91	95	97	93	150	90
No. of T-cell add-backs received at analysis	2	1	2	0	1	2	1	1
Day of T-cell add-backs	44, 72	25	56, 84	−	47	43, 72	45	34
Total T-cell add-back dose received at analysis	7	10	10	−	1	11	10	1

MDS indicates myelodysplastic syndrome; don, donor; pat, patient; and −, not applicable.

At analysis, all patients were in complete remission, did not have GVHD, and were not on immunosuppressive therapy.